The risk for angioedema increases when switching from an ARB or ACE inhibitor to ARNI, observational data suggest. Better to start RAS inhibition using the ARNI in the first place, researchers say.
Topline results of the STRONG-HF trial point to significant clinical benefit from a strategy featuring early initiation and rapid uptitration of meds for patients hospitalized with heart failure.
Patients with heart failure and mitral regurgitation should get at least 6 months of optimized guideline-directed medical therapy before invasive mitral repair is considered, researchers say.
Hyperkalemia is no reason for suboptimal guideline-directed heart failure medical therapy, given availability of at least one potassium-binding drug that seems to offer protection, researchers say.
There were fewer cardiac events at 2 years for MI patients with LVEF 40% to 49% discharged on beta blockers and, separately, renin-angiotensin-system inhibitors in a propensity-matched cohort study.